drugset / Trial / NCT03668600

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

NCT03668600

Phase 3 Terminated 230 enrolled Naurex, Inc
NaSingle-groupOpen-labelTreatment

Summary

Multicenter, open-label, long-term extended access treatment protocol in adult patients with a primary diagnosis of MDD.

Timeline

Start
2018-08-23
Primary completion
2019-07-03
Completion
2019-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Rapastinel Other / unclassified 450 mg Intravenous